{"protocolSection":{"identificationModule":{"nctId":"NCT01264549","orgStudyIdInfo":{"id":"STRAWINSKI"},"organization":{"fullName":"Charite University, Berlin, Germany","class":"OTHER"},"briefTitle":"Stroke Adverse Outcome is Associated With Nosocomial Infections: PCTus- Guided Antibacterial Therapy in Severe Ischemic Stroke Patients (STRAWINSKI)","officialTitle":"Stroke Adverse Outcome is Associated With Nosocomial Infections: PCTus- Guided Antibacterial Therapy in Severe Ischemic Stroke Patients","acronym":"STRAWINSKI"},"statusModule":{"statusVerifiedDate":"2021-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-12"},"primaryCompletionDateStruct":{"date":"2014-10","type":"ACTUAL"},"completionDateStruct":{"date":"2014-10","type":"ACTUAL"},"studyFirstSubmitDate":"2010-12-21","studyFirstSubmitQcDate":"2010-12-21","studyFirstPostDateStruct":{"date":"2010-12-22","type":"ESTIMATED"},"lastUpdateSubmitDate":"2021-12-15","lastUpdatePostDateStruct":{"date":"2022-01-04","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Andreas Meisel","investigatorTitle":"Prof. Dr. Andreas Meisel, Charité University, Berlin, Germany (Center for Stroke Research Berlin CSB & NeuroCure Clinical Research Center NCRC)","investigatorAffiliation":"Charite University, Berlin, Germany"},"leadSponsor":{"name":"Charite University, Berlin, Germany","class":"OTHER"},"collaborators":[{"name":"Brahms AG","class":"INDUSTRY"},{"name":"NeuroCure Clinical Research Center, Charite, Berlin","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"Development of stroke associated pneumonia (SAP) has a detrimental effect on stroke outcome. Biomarker-guided antibiotic treatment of patients at high risk for pneumonia may help to improve stroke outcome. Therefore, the investigators will evaluate whether intensified infection monitoring via Procalcitonin guiding an early standardized antibiotic treatment improves functional outcome after stroke compared with standard therapy based on current guidelines."},"conditionsModule":{"conditions":["Ischemic Stroke"],"keywords":["ischemic stroke","stroke-associated infections","biomarkers","PCT","immune and infection parameters"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":230,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"PCT guided arm","type":"EXPERIMENTAL","interventionNames":["Device: Procalcitonin assay - B.R.A.H.M.S PCT ultrasensitive Kryptor"]},{"label":"Control","type":"NO_INTERVENTION","description":"Standard treatment"}],"interventions":[{"type":"DEVICE","name":"Procalcitonin assay - B.R.A.H.M.S PCT ultrasensitive Kryptor","description":"The physician will be given access to a PCT value for Day 1 - 7. Depending on the PCT concentrations, the protocol recommends or discourages from the use of antibiotics","armGroupLabels":["PCT guided arm"],"otherNames":["Procalcitonin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Modified Rankin scale (mRS 0-6) score 0-4 adjusted for baseline modified Rankin score","description":"To assess the proportion of patients with a modified Rankin scale (mRS 0-6) score 0-4 at day 90 adjusted for baseline modified Rankin score.","timeFrame":"3 months after onset of symptoms (stroke)"}],"secondaryOutcomes":[{"measure":"Proportion of patients receiving any antibiotic therapy","description":"To assess the proportion of patients receiving any antibiotic therapy for any duration within 90 days.","timeFrame":"3 months after onset of symptoms (stroke)"},{"measure":"Modified Rankin scale adjusted for baseline modified Rankin score","description":"To assess the Modified Rankin scale at day 90 adjusted for baseline modified Rankin score.","timeFrame":"3 months after onset of symptoms (stroke)"},{"measure":"Barthel Index adjusted for baseline Barthel Index","description":"To assess the Barthel Index (BI 0-100) at day 90 adjusted for baseline Barthel Index.","timeFrame":"3 months after onset of symptoms (stroke)"},{"measure":"Modified Rankin scale (mRS) score 0-4 adjusted for baseline modified Rankin score","description":"To assess the proportion of patients with a modified Rankin scale (mRS) score 0-4 at day 180 adjusted for baseline modified Rankin score.","timeFrame":"6 months after onset of symptoms (stroke)"},{"measure":"Modified Rankin scale adjusted for baseline modified Rankin score","description":"To assess the modified Rankin scale at day 180 adjusted for baseline modified Rankin score.","timeFrame":"6 months after onset of symptoms (stroke)"},{"measure":"Barthel Index adjusted for baseline Barthel Index","description":"To assess the Barthel Index at day 180 adjusted for baseline Barthel Index.","timeFrame":"6 months after onset of symptoms (stroke)"},{"measure":"Days alive and out of hospital","description":"To assess the days alive and out of hospital at day 90.","timeFrame":"3 months after onset of symptoms (stroke)"},{"measure":"Time to first event of death, re-hospitalization or recurrent stroke","description":"To assess the time to first event of death, re-hospitalization or recurrent stroke.","timeFrame":"within 6 months after onset of symptoms (stroke)"},{"measure":"Proportion of events of post stroke infections","description":"To assess the proportion of events of post stroke infections to day 7.","timeFrame":"within 7 days after onset of symptoms (stroke)"},{"measure":"Proportion of events of post stroke infection or death","description":"To assess the proportion of events of post stroke infection or death to day 7.","timeFrame":"within 7 days after onset of symptoms (stroke)"},{"measure":"Medium number of days with fever (≥ 37,5°C) per patient","description":"To assess the medium number of days with fever (≥ 37,5°C) per patient to day 7.","timeFrame":"within 7 days after onset of symptoms (stroke)"},{"measure":"Stroke volume analysis","description":"To investigate the effect of an early PCT-guided antiinfective therapy on stroke volume.","timeFrame":"6 months after onset of symptoms (stroke)"},{"measure":"Length of hospital stay","description":"To assess the length of hospital stay after acute stroke.","timeFrame":"on discharge"},{"measure":"Hospital discharge disposition","description":"To assess the disposition on hospital discharge.","timeFrame":"on discharge"},{"measure":"shift analysis of the mRS"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* age ≥18 years\n* stroke onset within the last 40 hours before randomisation\n* clinical diagnosis of a severe (NIHSS \\> 9), non-lacunar stroke in the middle cerebral artery territory\n* consent given by the patient or by his/her legitimate representative where patients are incapable of giving consent themselves\n\nExclusion Criteria:\n\n* CT evidence of an intracerebral haemorrhage or a lacunar infarct as the probable cause of the current illness\n* Antibiotic use within the last 10 days\n* Suspected life expectancy of \\< 3 months\n* Participation in other interventional trials (on pharmaceuticals or medical devices)\n* Pregnancy, lactation\n* Pre-stroke mRS score ≥ 4","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Andreas Meisel, MD","affiliation":"Charité University Berlin (Center for Stroke Research Berlin CSB & NeuroCure Clinical Research Center NCRC)","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Stefan Anker, MD PhD","affiliation":"Charité University Berlin (Dept of Cardiology)","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Charite University (Center for Stroke Research Berlin CSB & NeuroCure Clinical Research Center NCRC)","city":"Berlin","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Unfallkrankenhaus Berlin Neurologie","city":"Berlin","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Vivantes Auguste Viktoria Klinikum Neurologie","city":"Berlin","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Vivantes Neukölln Neurologie","city":"Berlin","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Klinikum Frankfurt (Oder) Neurologie","city":"Frankfurt (Oder)","country":"Germany","geoPoint":{"lat":52.34714,"lon":14.55062}},{"facility":"Hospital Vall d'Hebron","city":"Barcelona","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}}]},"referencesModule":{"references":[{"pmid":"28484421","type":"RESULT","citation":"Ulm L, Hoffmann S, Nabavi D, Hermans M, Mackert BM, Hamilton F, Schmehl I, Jungehuelsing GJ, Montaner J, Bustamante A, Katan M, Hartmann A, Ebmeyer S, Dinter C, Wiemer JC, Hertel S, Meisel C, Anker SD, Meisel A. The Randomized Controlled STRAWINSKI Trial: Procalcitonin-Guided Antibiotic Therapy after Stroke. Front Neurol. 2017 Apr 24;8:153. doi: 10.3389/fneur.2017.00153. eCollection 2017."},{"pmid":"22925000","type":"RESULT","citation":"Ulm L, Ohlraun S, Harms H, Hoffmann S, Klehmet J, Ebmeyer S, Hartmann O, Meisel C, Anker SD, Meisel A. STRoke Adverse outcome is associated WIth NoSocomial Infections (STRAWINSKI): procalcitonin ultrasensitive-guided antibacterial therapy in severe ischaemic stroke patients - rationale and protocol for a randomized controlled trial. Int J Stroke. 2013 Oct;8(7):598-603. doi: 10.1111/j.1747-4949.2012.00858.x. Epub 2012 Aug 28."},{"pmid":"32098866","type":"RESULT","citation":"Hotter B, Hoffmann S, Ulm L, Montaner J, Bustamante A, Meisel C, Meisel A. Inflammatory and stress markers predicting pneumonia, outcome, and etiology in patients with stroke: Biomarkers for predicting pneumonia, functional outcome, and death after stroke. Neurol Neuroimmunol Neuroinflamm. 2020 Feb 25;7(3):e692. doi: 10.1212/NXI.0000000000000692. Print 2020 May."},{"pmid":"33280547","type":"RESULT","citation":"Hotter B, Hoffmann S, Ulm L, Meisel C, Bustamante A, Montaner J, Katan M, Smith CJ, Meisel A. External Validation of Five Scores to Predict Stroke-Associated Pneumonia and the Role of Selected Blood Biomarkers. Stroke. 2021 Jan;52(1):325-330. doi: 10.1161/STROKEAHA.120.031884. Epub 2020 Dec 7."},{"pmid":"29202730","type":"RESULT","citation":"Hotter B, Ulm L, Hoffmann S, Katan M, Montaner J, Bustamante A, Meisel A. Selection bias in clinical stroke trials depending on ability to consent. BMC Neurol. 2017 Dec 4;17(1):206. doi: 10.1186/s12883-017-0989-9."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000007239","term":"Infections"},{"id":"D000003428","term":"Cross Infection"},{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000020969","term":"Disease Attributes"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"},{"id":"D000007049","term":"Iatrogenic Disease"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M9973","name":"Infections","asFound":"Infection","relevance":"HIGH"},{"id":"M6058","name":"Communicable Diseases","relevance":"LOW"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M6332","name":"Cross Infection","asFound":"Nosocomial Infection","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M22390","name":"Disease Attributes","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"M9789","name":"Iatrogenic Disease","relevance":"LOW"},{"id":"T4202","name":"Oculocerebral Syndrome With Hypopigmentation","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC01","name":"Infections"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M3912","name":"Anti-Bacterial Agents","relevance":"LOW"},{"id":"M3914","name":"Antibiotics, Antitubercular","relevance":"LOW"}],"browseBranches":[{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}